ATE318598T1 - Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen - Google Patents

Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen

Info

Publication number: ATE318598T1
Authority: AT; Austria
Prior art keywords: pharmaceutical formulations; preferred; carboxylic acid; chemically stable; stable pharmaceutical
Prior art date: 1998-04-08

Application number

AT98958610T

Other languages

English (en)

Inventor

Philip C Lang

Original Assignee

Roberts Lab Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-08

Filing date

1998-11-16

Publication date

2006-03-15

1998-11-16 Application filed by Roberts Lab Inc filed Critical Roberts Lab Inc

2006-03-15 Application granted granted Critical

2006-03-15 Publication of ATE318598T1 publication Critical patent/ATE318598T1/de

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 5
239000003963 antioxidant agent Substances 0.000 title abstract 4
230000003078 antioxidant effect Effects 0.000 title abstract 2
230000006641 stabilisation Effects 0.000 title 1
238000011105 stabilization Methods 0.000 title 1
235000006708 antioxidants Nutrition 0.000 abstract 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 2
150000001735 carboxylic acids Chemical class 0.000 abstract 2
208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
239000003381 stabilizer Substances 0.000 abstract 2
239000004322 Butylated hydroxytoluene Substances 0.000 abstract 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
235000010323 ascorbic acid Nutrition 0.000 abstract 1
229960005070 ascorbic acid Drugs 0.000 abstract 1
239000011668 ascorbic acid Substances 0.000 abstract 1
235000010354 butylated hydroxytoluene Nutrition 0.000 abstract 1
229940095259 butylated hydroxytoluene Drugs 0.000 abstract 1
125000002843 carboxylic acid group Chemical group 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
150000003840 hydrochlorides Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
150000003457 sulfones Chemical class 0.000 abstract 1
150000003462 sulfoxides Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Anti-Oxidant Or Stabilizer Compositions (AREA)

AT98958610T 1998-04-08 1998-11-16 Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen ATE318598T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/057,260 US5962488A (en)	1998-04-08	1998-04-08	Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives

Publications (1)

Publication Number	Publication Date
ATE318598T1 true ATE318598T1 (de)	2006-03-15

Family

ID=22009506

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98958610T ATE318598T1 (de)	1998-04-08	1998-11-16	Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen

Country Status (7)

Country	Link
US (2)	US5962488A (de)
EP (1)	EP1067927B1 (de)
JP (1)	JP2003522724A (de)
AT (1)	ATE318598T1 (de)
CA (1)	CA2327708A1 (de)
DE (1)	DE69833684T2 (de)
WO (1)	WO1999052529A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5962488A (en) *	1998-04-08	1999-10-05	Roberts Laboratories, Inc.	Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
EP1151750A4 (de) *	1999-01-21	2003-05-14	Shionogi & Co	Medizinische zubereitung worin die entfärbung phenolischer hydroxylverbindungen verlangsamt ist
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007046411A1 (ja) *	2005-10-19	2007-04-26	Dainippon Sumitomo Pharma Co., Ltd.	イソキサゾール化合物の安定化方法
DE102007025275A1 (de) *	2007-05-31	2008-12-04	Qiagen Gmbh	Butendisäure oder deren Derivate zur Behandlung einer biologischen Probe
WO2009092601A1 (en)	2008-01-25	2009-07-30	Grünenthal GmbH	Pharmaceutical dosage form
CA2723438C (en)	2008-05-09	2016-10-11	Gruenenthal Gmbh	Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
SG186685A1 (en) *	2008-07-28	2013-01-30	Takeda Pharmaceutical	Pharmaceutical composition
WO2011009602A1 (en)	2009-07-22	2011-01-27	Grünenthal GmbH	Hot-melt extruded controlled release dosage form
PE20120572A1 (es)	2009-07-22	2012-06-06	Gruenenthal Chemie	Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion
PE20131102A1 (es)	2010-09-02	2013-10-12	Gruenenthal Chemie	Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
TWI516286B (zh)	2010-09-02	2016-01-11	歌林達股份有限公司	含陰離子聚合物之抗破碎劑型
DK2736497T3 (da)	2011-07-29	2017-11-13	Gruenenthal Gmbh	Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
LT2736495T (lt)	2011-07-29	2017-11-10	Grünenthal GmbH	Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
CA2864949A1 (en)	2012-02-28	2013-09-06	Grunenthal Gmbh	Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
RS57913B1 (sr)	2012-04-18	2019-01-31	Gruenenthal Gmbh	Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10154966B2 (en)	2013-05-29	2018-12-18	Grünenthal GmbH	Tamper-resistant dosage form containing one or more particles
AR096438A1 (es)	2013-05-29	2015-12-30	Gruenenthal Gmbh	Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
MX368846B (es)	2013-07-12	2019-10-18	Gruenenthal Gmbh	Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
EP3073994A1 (de)	2013-11-26	2016-10-05	Grünenthal GmbH	Herstellung einer pulverförmigen pharmazeutischen zusammensetzung mittels kryogenen mahlens
JP2017518980A (ja)	2014-05-12	2017-07-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	タペンタドールを含む、改変防止即時放出カプセル製剤
US9872835B2 (en)	2014-05-26	2018-01-23	Grünenthal GmbH	Multiparticles safeguarded against ethanolic dose-dumping
JP2018517676A (ja)	2015-04-24	2018-07-05	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	即時放出および溶媒抽出に対する耐性を有する改変防止製剤
ES2920394T3 (es) *	2015-06-23	2022-08-03	Intervet Int Bv	Solución de isoxazolina que contiene vitamina E para usar con agua potable desinfectada
US10842750B2 (en)	2015-09-10	2020-11-24	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations
MX2023003783A (es) *	2020-10-01	2023-04-26	Imago Biosciences Inc	Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB679192A (en) *	1948-07-09	1952-09-17	Eastman Kodak Co	Method of stabilizing fats and fatty oils against oxidation
GB682205A (en) *	1949-03-16	1952-11-05	Eastman Kodak Co	Improvements in and relating to anti-oxidants for oils and fats
US4091091A (en) *	1973-11-08	1978-05-23	Eli Lilly And Company	Stabilized nitroglycerin tablets
JPS5299242A (en) *	1976-02-12	1977-08-19	Tanabe Seiyaku Co	Antiioxidant
JPS62153385A (ja) *	1985-12-27	1987-07-08	Riken Vitamin Co Ltd	酸化防止剤
US4837031A (en) *	1987-09-17	1989-06-06	Mallinckrodt, Inc.	Compositions containing ibuprofen
CA1335106C (en) *	1989-02-27	1995-04-04	John Mehnert Schaus	Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
US5420151A (en) *	1989-12-22	1995-05-30	Aktiebolaget Astra	Chroman derivatives
CA2048846A1 (en) *	1990-08-15	1992-02-16	Craig Steven Hoechstetter	Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes, 3-aminochromanes, and aminothiochromanes
JPH06500594A (ja) *	1991-01-07	1994-01-20	カビ　ファルマシア　アクチェボラーグ	多不飽和油の安定化のための天然酸化防止剤の組成物
US5077069A (en) *	1991-01-07	1991-12-31	Kabi Pharmacia Ab	Composition of natural antioxidants for the stabilization of polyunsaturated oils
JPH05339154A (ja) *	1992-06-03	1993-12-21	Sagami Chem Res Center	肝機能改善剤
US5434174A (en) *	1992-07-17	1995-07-18	Eli Lilly And Company	Isoxazole derivatives for the treatment of irritable bowel syndrome
JPH0717855A (ja) *	1992-09-02	1995-01-20	Maruha Corp	脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
CN1060040C (zh) *	1993-10-25	2001-01-03	默里尔药物公司	稳定的丁苯哌丁醇与布洛芬的药物组合物
JPH09194362A (ja) *	1996-01-19	1997-07-29	Bizen Kasei Kk	ドコサヘキサエン酸及びエイコサペンタエン酸含有リン脂質を含む組成物
JP3941073B2 (ja) *	1996-03-01	2007-07-04	日本油脂株式会社	油脂組成物及びそれを含む食品
US5962488A (en) *	1998-04-08	1999-10-05	Roberts Laboratories, Inc.	Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives

1998
- 1998-04-08 US US09/057,260 patent/US5962488A/en not_active Expired - Fee Related
- 1998-11-16 JP JP2000543139A patent/JP2003522724A/ja active Pending
- 1998-11-16 AT AT98958610T patent/ATE318598T1/de not_active IP Right Cessation
- 1998-11-16 EP EP98958610A patent/EP1067927B1/de not_active Expired - Lifetime
- 1998-11-16 DE DE69833684T patent/DE69833684T2/de not_active Expired - Fee Related
- 1998-11-16 CA CA002327708A patent/CA2327708A1/en not_active Abandoned
- 1998-11-16 WO PCT/US1998/024471 patent/WO1999052529A1/en not_active Ceased
1999
- 1999-04-12 US US09/290,904 patent/US6479529B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US5962488A (en)	1999-10-05
CA2327708A1 (en)	1999-10-21
EP1067927A4 (de)	2003-04-23
DE69833684D1 (de)	2006-04-27
DE69833684T2 (de)	2006-11-16
EP1067927B1 (de)	2006-03-01
EP1067927A1 (de)	2001-01-17
WO1999052529A1 (en)	1999-10-21
US6479529B1 (en)	2002-11-12
JP2003522724A (ja)	2003-07-29

Legal Events

Date	Code	Title	Description
2006-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE318598T1 (de)	2006-03-15	Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen
ZA200501715B (en)	2005-11-30	Solution for ungual application
EA200400730A1 (ru)	2005-02-24	Ингалятор контролируемой дозы
RU2009112207A (ru)	2010-10-10	Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью
DK0722313T3 (da)	1999-11-15	Viskoelastiske sammensætninger af fluorerede organiske forbindelser
ATE448194T1 (de)	2009-11-15	Verwendung einer pharmazeutischen zusammensetzung mit einem para-aminophenylessigsäurederivat für die behandlung von entzündlichen erkrankungen des magen-darmtrakts
CA2108903A1 (en)	1992-11-04	Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
DE60317039D1 (de)	2007-12-06	Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben
BR0311460A (pt)	2005-03-29	Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
DE69805983D1 (de)	2002-07-18	Hustenhemmende, theobromine enthaltende zusammensetzungen
MD1688F2 (en)	2001-06-30	Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection
JPS617252A (ja)	1986-01-13	安定化された透明過酸化ベンゾイル組成物
ATE84045T1 (de)	1993-01-15	Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen.
HU9203286D0 (en)	1992-12-28	Inflammation inhibiting hydrosame acids and n-hydroxi-ureas
IT1251166B (it)	1995-05-04	Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
ES2106531T3 (es)	1997-11-01	Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
ATE386523T1 (de)	2008-03-15	Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
EA199901012A1 (ru)	2000-08-28	Фармацевтические композиции на основе тизоксанида и нитазоксанида
NO912414D0 (no)	1991-06-20	Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
NO932843L (no)	1994-02-14	Farmasoeytiske preparater
IE781425L (en)	1979-01-15	Injectable chloroamphenicol solution
DE3476160D1 (en)	1989-02-23	Derivatives of benzoic acid for use as a medicament and use of these derivatives as conserving or disinfecting agent
FI932654A0 (fi)	1993-06-10	Hydroxamsyraderivat, som hindrar lipoxigenas
DE69414396D1 (de)	1998-12-10	Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
DK1100463T3 (da)	2003-01-20	Injicerbare formuleringer indeholdende ramoplanin